Evaluation of Pneumococcal Vaccine Formulations in Elderly

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00756067
First received: September 18, 2008
Last updated: September 3, 2009
Last verified: September 2009
  Purpose

The purpose of this observer-blind study is to evaluate the safety, reactogenicity and immunogenicity of pneumococcal vaccines in elderly. Subjects will be vaccinated twice with an interval of two months.


Condition Intervention Phase
Diseases Caused by Streptococcus Pneumoniae and Non-typable Haemophilus Influenzae, Elderly
Biological: Pneumococcal vaccine GSK2189241A
Biological: Pneumo 23™
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Study to Evaluate GSK Biologicals' Candidate Formulations of Pneumococcal Vaccines (GSK2189241A) in Elderly Subjects.

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Occurrence of any vaccine related and grade 3 solicited local and general adverse events [ Time Frame: During a 7-day follow up period after each vaccine dose ] [ Designated as safety issue: No ]
  • Occurrence of any vaccine related and grade 3 unsolicited adverse events [ Time Frame: During a 31-day follow up period after each vaccine dose ] [ Designated as safety issue: No ]
  • Occurrence of any vaccine related serious adverse events (SAE) [ Time Frame: From dose 1 to study conclusion ] [ Designated as safety issue: No ]
  • Occurrence of any grade 3 laboratory abnormalities [ Time Frame: At 1 and 7 days after each vaccine dose ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Occurrence of any solicited local and general adverse events [ Time Frame: During a 7-day follow up period after each vaccine dose ] [ Designated as safety issue: No ]
  • Occurrence of any unsolicited adverse events [ Time Frame: During a 31-day follow up period after each vaccine dose ] [ Designated as safety issue: No ]
  • Occurrence of any laboratory abnormalities [ Time Frame: At 1 and 7 days after each vaccine dose ] [ Designated as safety issue: No ]
  • Occurrence of any medically significant conditions prompting emergency room visits or physician visits regardless of casual relationship to vaccination or intensity [ Time Frame: From dose 1 to study conclusion ] [ Designated as safety issue: No ]
  • Anti-pneumococcal and anti-NTHi candidate vaccine antigens [ Time Frame: At Days 0, 30 and 90 ] [ Designated as safety issue: No ]

Enrollment: 168
Study Start Date: September 2008
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Formulation 5 Biological: Pneumococcal vaccine GSK2189241A
Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.
Experimental: Formulation 2 Biological: Pneumococcal vaccine GSK2189241A
Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.
Experimental: Formulation 6 Biological: Pneumococcal vaccine GSK2189241A
Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.
Experimental: Formulation 1 Biological: Pneumococcal vaccine GSK2189241A
Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.
Active Comparator: 23 valent pneumococcal vaccine Biological: Pneumo 23™
One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2.
Experimental: Formulation 3 Biological: Pneumococcal vaccine GSK2189241A
Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.
Experimental: Formulation 4 Biological: Pneumococcal vaccine GSK2189241A
Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.

  Eligibility

Ages Eligible for Study:   65 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects who the investigator believes will comply with the requirements of the protocol should be enrolled in the study.
  • Male or female subjects between, and including, 65 and 85 years old at the time of the first vaccination, in relatively stable health.
  • Written informed consent obtained from the subject.

Exclusion Criteria:

  • Previous vaccination against Streptococcus pneumoniae (with a licensed vaccine or with an investigational candidate vaccine).
  • Vaccination with diphtheria/tetanus toxoids within one month preceding the first dose of study vaccine.
  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period or participation to another pharmaceutical/vaccine study.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
  • Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of study vaccine, with the exception of the influenza vaccine which can be administered at least 7 days preceding or at least 7 days following any vaccine dose.
  • Administration of immunoglobulins and/or any blood products within the last 3 months.
  • Bacterial pneumonia within 3 years prior to 1st vaccination.
  • Invasive pneumococcal disease (I.P.D) within 3 years prior to 1st vaccination.
  • History of thrombocytopenia or bleeding disorder.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
  • History of reactions or allergic disease likely to be exacerbated by any component of the vaccine.
  • History of administration of an experimental/licensed vaccine containing MPL or QS21.
  • Current serious neurologic or mental disorders.
  • Inflammatory processes such as known chronic active infections (e.g. Hepatitis B, C).
  • All past or current malignancies (excluding non-melanic skin cancer) and lymphoproliferative disorders diagnosed or treated actively during the past 5 years.
  • Acute disease at the time of enrolment.
  • Physical examination positive for acrocyanosis, jaundice, splenomegaly
  • Acute or chronic, clinically significant anaemia, pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by history, physical examination or laboratory screening tests at the discretion of the investigator.
  • Laboratory evidence of haematological abnormalities.
  • Laboratory evidence of biochemical abnormalities.
  • History of chronic alcohol consumption and/or drug abuse.
  • Other conditions that the principal investigator judges may interfere with study findings.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00756067

Locations
Sweden
GSK Investigational Site
Malmö, Sweden, SE-205 02
GSK Investigational Site
Uppsala, Sweden, SE-751 85
GSK Investigational Site
Örebro, Sweden, SE-701 85
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided by GlaxoSmithKline

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Study Director, GSK
ClinicalTrials.gov Identifier: NCT00756067     History of Changes
Other Study ID Numbers: 111652
Study First Received: September 18, 2008
Last Updated: September 3, 2009
Health Authority: Sweden: Medical Products Agency

Keywords provided by GlaxoSmithKline:
Streptococcus pneumoniae
pneumococcal vaccine

Additional relevant MeSH terms:
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections

ClinicalTrials.gov processed this record on October 30, 2014